This episode currently has no reviews.
Submit ReviewQ1 is in the books, and stocks are heading into Q2 with some major accomplishments. Can the market rally keep raging? And where you should be positioned going into the second quarter. Plus… what it really costs to craft these diabetes drugs. A new study pointing to a $5 price tag for a month’s worth of one blockbuster GLP-1 drug. The dollar dichotemy… and if prices will come down for the public.
This episode currently has no reviews.
Submit ReviewThis episode could use a review! Have anything to say about it? Share your thoughts using the button below.
Submit Review